SCHEMBL850359

SCHEMBL850359

C=C(C)C(=O)NC(CC)[Si](O[SiH2]C(C)(C)C)(O[SiH2]C(C)(C)C)O[SiH2]C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL850358 0.89 TGFBR1 (0.33) TGFBR1
SCHEMBL135381 0.78 TGFBR1 (0.41) TGFBR1
SCHEMBL10751506 0.77 TGFBR1 (0.35) TGFBR1
SCHEMBL79937 0.76 TGFBR1 (0.40) TGFBR1
SCHEMBL308679 0.75 TGFBR1 (0.39) TGFBR1
SCHEMBL514780 0.74 TGFBR1 (0.38) TGFBR1
SCHEMBL1517401 0.73 TGFBR1 (0.37) TGFBR1
SCHEMBL10753309 0.73 TGFBR1 (0.37) TGFBR1
SCHEMBL10751465 0.73 TGFBR1 (0.37) TGFBR1
SCHEMBL12094902 0.71 TGFBR1 (0.41) TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432808-B1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS NOVARTIS AG (CH) 2015-10-21 EP claimed
US-9097839-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2015-08-04 US claimed
US-8383744-B2 Actinically-crosslinkable siloxane-containing copolymers NOVARTIS AG (CH) 2013-02-26 US claimed
US-20120172478-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2012-07-05 US claimed
US-8163206-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2012-04-24 US claimed
EP-2432808-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS Novartis AG (CH) 2012-03-28 EP claimed
EP-2374031-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES Novartis AG (CH) 2011-10-12 EP claimed
WO-2010133680-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS NOVARTIS AG (CH) 2010-11-25 WO claimed
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS ALCON INC. (CH) 2010-11-25 US claimed
US-20100258961-A1 Method for making silicone hydrogel contact lenses ALCON INC. (CH) 2010-10-14 US claimed
WO-2010071691-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES NOVARTIS AG (CH) 2010-06-24 WO claimed
EP-3486711-A1 LENS-FORMING MATERIALS COMPRISING PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES Novartis AG (CH) 2019-05-22 EP disclosed
EP-1927882-B1 Contact lens NOVARTIS AG (CH) 2015-09-23 EP disclosed
US-9097839-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2015-08-04 US disclosed
US-9066981-B2 Actinically-crosslinkable siloxane-containing copolymers NOVARTIS AG (CH) 2015-06-30 US disclosed
US-6649722-B2 Interpolymerization product of a (a) hydrophilic monomer with (b) a tris(siloxy)silyl group- containing monomer, (c) a wide variety of hydrophobic monomers (both aliphatic and aromatic) and usually a (d) polyfluorinated monomer NOVARTIS AG (CH) 2003-11-18 US disclosed
US-20020107337-A1 Contact lens ALCON INC. (CH) 2002-08-08 US disclosed
EP-0675910-A1 NOVEL MACROMONOMERS. BAUSCH & LOMB (US) 1995-10-11 EP disclosed
US-5387663-A Polymerized with hydrophilic or hydrophobic monomers for biomedical devices, contact lenses BAUSCH & LOMB INCORPORATED (US) 1995-02-07 US disclosed
US-5336797-A Polymerizable with acrylic monomers and acrylated polyethers; contact lenses BAUSCH & LOMB INCORPORATED (US) 1994-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS VCL, MACF1, CFL1 TGFBR1 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.